Cargando…

Identification and Validation of STAT6 as a Prognostic and Predictive Biomarker in Acute Myeloid Leukemia

BACKGROUND: Acute myeloid leukemia (AML) is one of the most common hematological diseases in adults. The overall survival rate remains unsatisfactory. It is urgent to identify potential prognostic biomarkers and develop new molecular therapeutic strategies for AML. Signal transducer and activator of...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wei, Zhu, Feiyue, Yan, Jiazhuo, Liu, Yi, Chen, Cong, Zhang, Kaixuan, Zhao, Xielan, Chen, Jingyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648156/
https://www.ncbi.nlm.nih.gov/pubmed/33173308
http://dx.doi.org/10.2147/OTT.S272757
_version_ 1783607056637362176
author Liu, Wei
Zhu, Feiyue
Yan, Jiazhuo
Liu, Yi
Chen, Cong
Zhang, Kaixuan
Zhao, Xielan
Chen, Jingyuan
author_facet Liu, Wei
Zhu, Feiyue
Yan, Jiazhuo
Liu, Yi
Chen, Cong
Zhang, Kaixuan
Zhao, Xielan
Chen, Jingyuan
author_sort Liu, Wei
collection PubMed
description BACKGROUND: Acute myeloid leukemia (AML) is one of the most common hematological diseases in adults. The overall survival rate remains unsatisfactory. It is urgent to identify potential prognostic biomarkers and develop new molecular therapeutic strategies for AML. Signal transducer and activator of transcription (STAT) is a family of genes that encode intracellular transcription factors. STATs are associated with leukemogenesis, cellular transformation, and cell cycle in AML. METHODS: We used sequencing data and clinical data from The Cancer Genome Atlas (TCGA) and ONCOMINE to identify expression difference, gene variability and correlation as well as prognostic effects of STAT genes in AML patients. Then, we verified the expression difference of STAT6 between healthy control and AML patients and its prognostic impact in Gene Expression Omnibus (GEO) database and our own recruited cohort. RESULTS: The mRNA level of STAT6 was increased in AML patients among TCGA, GEO and ONCOMINE public datasets and was found to be an independent risk factor of overall survival in all AML patients and patients who only received chemotherapy by multivariate analysis. In our study, STAT6 mRNA level was markedly up-regulated in AML patients (n=105) compared to healthy donor (n=39) (P=0.0435) as a validated cohort. Patients that only received chemotherapy in high STAT6 group showed significantly lower overall survival (OS) (P=0.0055). CONCLUSION: STAT6 expression was increased in AML patients. STAT6 was found to be an adverse prognosis factor in AML patients, especially those who only received chemotherapy treatments.
format Online
Article
Text
id pubmed-7648156
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-76481562020-11-09 Identification and Validation of STAT6 as a Prognostic and Predictive Biomarker in Acute Myeloid Leukemia Liu, Wei Zhu, Feiyue Yan, Jiazhuo Liu, Yi Chen, Cong Zhang, Kaixuan Zhao, Xielan Chen, Jingyuan Onco Targets Ther Original Research BACKGROUND: Acute myeloid leukemia (AML) is one of the most common hematological diseases in adults. The overall survival rate remains unsatisfactory. It is urgent to identify potential prognostic biomarkers and develop new molecular therapeutic strategies for AML. Signal transducer and activator of transcription (STAT) is a family of genes that encode intracellular transcription factors. STATs are associated with leukemogenesis, cellular transformation, and cell cycle in AML. METHODS: We used sequencing data and clinical data from The Cancer Genome Atlas (TCGA) and ONCOMINE to identify expression difference, gene variability and correlation as well as prognostic effects of STAT genes in AML patients. Then, we verified the expression difference of STAT6 between healthy control and AML patients and its prognostic impact in Gene Expression Omnibus (GEO) database and our own recruited cohort. RESULTS: The mRNA level of STAT6 was increased in AML patients among TCGA, GEO and ONCOMINE public datasets and was found to be an independent risk factor of overall survival in all AML patients and patients who only received chemotherapy by multivariate analysis. In our study, STAT6 mRNA level was markedly up-regulated in AML patients (n=105) compared to healthy donor (n=39) (P=0.0435) as a validated cohort. Patients that only received chemotherapy in high STAT6 group showed significantly lower overall survival (OS) (P=0.0055). CONCLUSION: STAT6 expression was increased in AML patients. STAT6 was found to be an adverse prognosis factor in AML patients, especially those who only received chemotherapy treatments. Dove 2020-11-02 /pmc/articles/PMC7648156/ /pubmed/33173308 http://dx.doi.org/10.2147/OTT.S272757 Text en © 2020 Liu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Liu, Wei
Zhu, Feiyue
Yan, Jiazhuo
Liu, Yi
Chen, Cong
Zhang, Kaixuan
Zhao, Xielan
Chen, Jingyuan
Identification and Validation of STAT6 as a Prognostic and Predictive Biomarker in Acute Myeloid Leukemia
title Identification and Validation of STAT6 as a Prognostic and Predictive Biomarker in Acute Myeloid Leukemia
title_full Identification and Validation of STAT6 as a Prognostic and Predictive Biomarker in Acute Myeloid Leukemia
title_fullStr Identification and Validation of STAT6 as a Prognostic and Predictive Biomarker in Acute Myeloid Leukemia
title_full_unstemmed Identification and Validation of STAT6 as a Prognostic and Predictive Biomarker in Acute Myeloid Leukemia
title_short Identification and Validation of STAT6 as a Prognostic and Predictive Biomarker in Acute Myeloid Leukemia
title_sort identification and validation of stat6 as a prognostic and predictive biomarker in acute myeloid leukemia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648156/
https://www.ncbi.nlm.nih.gov/pubmed/33173308
http://dx.doi.org/10.2147/OTT.S272757
work_keys_str_mv AT liuwei identificationandvalidationofstat6asaprognosticandpredictivebiomarkerinacutemyeloidleukemia
AT zhufeiyue identificationandvalidationofstat6asaprognosticandpredictivebiomarkerinacutemyeloidleukemia
AT yanjiazhuo identificationandvalidationofstat6asaprognosticandpredictivebiomarkerinacutemyeloidleukemia
AT liuyi identificationandvalidationofstat6asaprognosticandpredictivebiomarkerinacutemyeloidleukemia
AT chencong identificationandvalidationofstat6asaprognosticandpredictivebiomarkerinacutemyeloidleukemia
AT zhangkaixuan identificationandvalidationofstat6asaprognosticandpredictivebiomarkerinacutemyeloidleukemia
AT zhaoxielan identificationandvalidationofstat6asaprognosticandpredictivebiomarkerinacutemyeloidleukemia
AT chenjingyuan identificationandvalidationofstat6asaprognosticandpredictivebiomarkerinacutemyeloidleukemia